We read with great interest the article of Sessa et al.1, which indicates superior performance in identifying children at higher cardiometabolic risk, including kidney damage, by focusing on metabolic dysfunction-associated steatotic liver disease (MASLD)2 compared to non-alcoholic fatty liver disease (NAFLD) in the context of obesity. The authors suggest that individuals with MASLD exhibit a more unfavorable cardiovascular and metabolic risk profile when compared to those with NAFLD.
